Within hours after infection of cells with herpes simplex, vaccinia, influenza, or Newcastle disease virus, new antigens appeared on the surface of infected cells. The interaction of specific antiviral antibody and complement with these antigens resulted iii cell destruction, which was quantitated by the release of 5'Cr. A number of factors can influence the degree of cell destruction, including the density of viral antigens on the surface of infected cells, the nature of the antiviral antibody, and the presence of anti-immunoglobulins. The immunological destruction of virus-infected cells may on the one hand serve as a defense mechanism against certain viral infections, while on the other hand it may contribute to the pathology of the host.
Several lines of evidence suggest that the immune response of the host may contribute to the pathogenesis of certain viral infections. First, replication of viruses in the cells of the immune system may affect the functional capacity of the immune system and thereby result in immunological derangements (1) . Second, the immune response of the host to viral antigens may lead to the formation of circulating virus-antibody complexes and the development of immune-complex type of glomerulonephritis (2, 3) . Third, the interaction of sensitized lymphocytes or antiviral antibody and complement with virus-induced cell surface antigens may result in cellular injury (4) . The present report describes a quantitative in vitro system for the study of the destruction of virus-infected cells by antiviral antibody and complement, and discusses some of the factors that can inhibit or enhance the degree of immunological injury.
MATERIALS AND METHODS
Tissue Culture and Media. Primary rabbit kidney cells were prepared and maintained as described (5) . HeLa and WI-38 cells were purchased from Microbiological Associates, Bethesda, Md. Growth medium consisted of Eagle's minimal essential medium-0.5% lactalbumin hydrolysate-10% heatinactivated calf serum-antibiotics (per ml; 100 units of penicillin, 50 ug of neomycin and 100 units of mycostatin).
Viruses. Herpes simplex virus (HSV) (type 1), and vaccinia virus (CVI-79) were propagated and assayed in primary rabbit kidney cells (5) . Influenza virus (PR-8) and Newcastle disease virus (NDV) were grown in 10-day-old embryonated hen's eggs and assayed by hemagglutination.
Antisera. Antisera against HSV were prepared as described (5) by immunization of New Zealand white rabbits with either Abbreviations: HSV, Herpes simplex virus; NDV, Newcastle disease virus; CH5o, complement hemolytic titer50, which indicates 50% hemolysis; NRS, normal rabbit serum. 3073 a single or multiple intravenous injections of partially purified virus. Hyperimmune sera against vaccinia, influenza, and NDV were prepared by injection of rabbits at various intervals with virus in Freund's complete adjuvant. The 50% neutralization titers of the hyperimmune sera against HSV and vaccinia were greater than 1: 2000 and the hemagglutination inhibition titers of the anti-influenza and anti-NDV sera were greater than 1:1000. Sera from unimmunized rabbits served as controls and all sera were heated at 560C for 30 min before use.
The IgG and IgM fractions of anti-HSV serum were prepared by Sephadex G-200 chromatography. Fab fragments were prepared by papain digestion of the IgG fraction from hyperimmune rabbit serum as described (6) . The protein concentration of the Fab fragments (undiluted) was 3.9 mg/ ml and the 50% neutralization titer against HSV was 1: 80.
Antiserum against rabbit serum was prepared in goats (goat anti-rabbit serum); before use, the antiserum was absorbed twice with primary rabbit kidney cells.
Complement. Pooled rabbit serum obtained from New Zealand white rabbits served as the source of complement.
"Cr Assay. Confluent monolayers, in 35-mm Petri dishes, containing about 1.0 times 106-0 cells were washed with phosphate-buffered saline (PBS, pH 7.4) and then incubated at 370C with 2-7 MCi/ml of [5' Cr]sodium chromate. After 90 The data in Table 1 show that treatment of infected monolayers with anti-HSV serum and complement resulted in the release of about 10,900 cpm into the cell-free supernatant. Less than 500 cpm were found in the pellet. The release of 51Cr into the cell-free supernatant was associated with a corresponding decrease in the5"Cr content of the monolayers. In contrast, when infected cells were treated with either anti-HSV serum plus heat-inactivated complement or normal rabbit serum plus complement, less than 1000 cpm were released. Similarly, very little 61Cr was released when uninfected monolayers were treated with anti-HSV serum and complement.
To compare immunological injury as measured by the release of 56Cr with trypan blue exclusion, infected cells were incubated with serial dilutions of anti-HSV serum and complement. Fig. 1 shows that as the concentration of anti-HSV serum was increased, there was a corresponding decrease in the number of viable cells remaining in the monolayers and a corresponding increase in the release of 61Cr into the cell-free supernatant. These findings indicate that the release of 51Cr is a good index of immunological injury.
Time of appearance of HSV-induced antigens on the surface of infected cells
To determine how soon after infection cells become susceptible to immunological injury, monolayers were infected with HSV and at intervals thereafter treated with anti-HSV serum and complement. Fig. 2 shows that within 6 hr after infection, new antigens appeared on the surface of the infected cells. Immunological injury of cells infected with vaccinia, influenza, or NDV Primary rabbit kidney cells were infected with vaccinia, influenza, or NDV and at various times thereafter, the monolayers were incubated with specific antiviral antibody and complement (Fig. 5) . Treatment of vaccinia-infected cells with antivaccinia antibody and complement, or treatment of influenza-infected cells with anti-influenza antibody and complement resulted in a 4-fold increase in the release of 5'Cr within 9-12 hr after infection. Treatment of NDV-infected cells with anti.-NDV antibody and complement resulted in a significant release of 51Cr within 3-6 hr after infection.
The specificity of antibody-mediated immunological injury is illustrated in Table 2 tively. These findings suggest that each virus induced different antigens on the surface of the infected cells and that these antigens were recognized only by specific antiviral antibody.
Properties of cytolytic anti-HSV antibody
After a single intravenous injection of HSV in rabbits, cytolytic activity was detected within 6 days after immunization and maximal activity was observed between 15 and 21 days. The time of appearance of cytolytic antibody corresponded closely to the time of appearance of neutralizing antibody. 
Effect of anti-immunoglobulins on immunological injury
The data in Fig. 7 show that immunological injury also can be inhibited by anti-immunoglobulins directed against the antiviral antibody that is attached to infected cells. Infected monolayers were incubated for 30 min with different concentrations of rabbit anti-HSV. Normal rabbit serum was used as the control. The sensitized cells were washed and incubated for another 30 min with either goat anti-rabbit serum or normal goat serum. The monolayers then were washed and incubated for 60 min with complement. The amount of 5'Cr released was determined and the percentage inhibition by goat anti-rabbit serum was calculated. Fig. 7 shows that the percentage inhibition was dependent on both the concentration of anti-HSV used to sensitize the cells and the concentration of goat anti-rabbit serum. When infected cells were sensitized with a 1: 8 dilution of the anti-HSV, the highest concentration of goat anti-rabbit serum (1:2) inhibited the release of 5'Cr by over 80%. However, when infected cells were sensitized with 1:16 and 1: 32 dilutions of anti-HSV, the highest concentration of goat anti-rabbit serum (1:2) produced only 58 and 25% inhibition, respectively.
When even lower concentrations of anti-HSV were used to sensitize infected cells, the addition of goat anti-rabbit serum not only failed to inhibit immunological injury, but actually enhanced immunological injury. Fig. 8 shows that the goat anti-rabbit serum increased the amount of 51Cr released from cells that had been sensitized with a 1:64 and 1: 128 dilution of anti-HSV by as much as 275 and 600%7o, respectively, above the appropriate controls. In the absence of anti-HSV, neither goat anti-rabbit serum nor normal goat serum had any effect on the release of 5'Cr. Thus, whether imunological injury is inhibited or enhanced depends on the density of antiviral antibodies on the surface of infected cells and on the concentration of anti-immunoglobulin that is available to react with the antiviral antibodies. Immunological Injury of Virus-Infected Cells 3077 antiviral antibody and complement with virus-induced cellsurface antigens may be a relatively common phenomenon that is associated with various acute, recurrent, and persistent viral infections (7) (8) (9) (10) .
The degree of immunological injury produced by virusspecific antibody and complement may be influenced by a number of factors. One of these factors may be the density of viral antigens on the surface of infected cells. On the basis of current immunological concepts, the further apart the antigenic sites, the less likely that complement-fixing IgG doublets will form (11, 12) . Thus, if a particular virus produces few, if any, new antigenic sites or if the antigenic sites are widely separated, complement-dependent cell injury may not occur. If, however, during the course of an infection, the density of viral antigens on the surface of infected cells should increase (13) , this would enhance the likelihood of doublet formation with IgG and this in turn might increase the degree of complement-dependent cell injury. Also, it has been suggested that there are differences in the inherent sensitivity of cell membranes to immune lysis by complement (9) . These differences may determine whether or not a given cell type, when infected with a particular virus, would be lysed by specific antiviral antibody and complement. These factors might be particularly important in the pathogenesis of "slow virus" infections.
The nature of the antiviral immunoglobulin also may be an important factor in producing immune lysis. Our experiments showed that the attachment of antiviral immunoglobulins that do not fix complement (i.e., Fab fragments) to viral antigens on the surface of infected cells can block the attachment of complement-fixing antiviral immunoglobulins and thereby inhibit immune lysis. This points to the possibility that in vivo, naturally-occurring antiviral antibody that does not fix complement (e.g., IgA, -yl) might competitively interfere with the attachment of complement-fixing antiviral antibody and thereby prevent immunological injury. If this proves to be the case, the ratio of antiviral antibody that fixes complement to antiviral antibody that does not fix complement may determine the extent of immunological injury in a particular infection. Moreover, the attachment of sublytic concentrations of antiviral antibody to viral antigens on the surface of infected cells might prevent sensitized lymphocytes from recognizing or reacting with these antigens and thereby inhibit the cellular immune response. In viral infections, this might prove to be the counterpart of "blocking antibody" or "immunological enhancement" (14) .
Immunological injury also can be influenced by anti-immunoglobulins. When infected cells were sensitized with high concentrations of antiviral antibody, anti-immunoglobulins inhibited cell destruction. The attachment of anti-immunoglobulins to the antiviral antibody on the surface of the infected cells presumably blocked complement-fixing sites or prevented the components of complement from reaching the surface of the infected cells. Conversely, when the infected cells were sensitized with concentrations of antiviral antibody that produced little or no cell destruction, anti-immunoglobulins enhanced cell destruction; presumably, the anti-immunoglobulins formed doublets with the antiviral immunoglobulin on the surface of the infected cells and thereby increased the total number of complement-fixing sites. Whether rheumatoid factor or other naturally occurring anti-immunoglobulins also might combine in vitro or in vivo with antiviral immunoglobulins on the surface of infected cells and thereby enhance or depress the degree of immunological injury remains to be determined.
Immunologically mediated destruction of virus-infected cells may have beneficial as well as deleterious effects on the host. The recognition of viral antigens on the surface of infected cells by antiviral antibody and the destruction of these cells by complement provides the host with a highly specific, rapid, and potentially effective defense mechanism. The immunological destruction of virus-infected cells would shut off virus replication and release or expose the infectious virus within the cells to neutralizing antibody. In addition, antibodymediated destruction of virus-infected cells may be one of the mechanisms by which the host combats those viruses that avoid neutralization by spreading directly from cell to cell. Thus, in viral infections, antibody-mediated cell destruction may fulfill much of the role that has been postulated for cellular immunity (15) . This does not mean that cellular immunity does not play an important role in the defense against virusinfected cells, but suggests that antibody-mediated cell destruction may serve as an effective alternate defense mechanism.
Although, many investigators have speculated that immunological injury may contribute to the pathology of certain viral infections, it has been difficult to dissect and evaluate this phenomenon in vivo. Our studies indicate that the release of 5'Cr from virus-infected cells by antiviral antibody and complement offers a simple, objective, and quantitative technique for studying immunological injury in vitro. By use of this technique it should be possible to study various viruses, to determine the effect of these viruses on different cell types, and to evaluate the role of cytolytic versus noncytolytic antibody in the serum of patients during the course of different viral infections.
